Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14806639 | 1.00 | HSD11B1 (0.37) | HSD11B1HSD11B2VNN1CHRNB2CHRNB4 | |
| SCHEMBL616990 | 1.00 | HSD11B1 (0.37) | HSD11B1HSD11B2VNN1CHRNB2CHRNB4 | |
| SCHEMBL15640955 | 1.00 | HSD11B1 (0.37) | HSD11B1HSD11B2VNN1CHRNB2CHRNB4 | |
| SCHEMBL21460094 | 0.88 | VNN1 (0.39) | HSD11B1HSD11B2VNN1 | |
| SCHEMBL6127513 | 0.85 | HSD11B1 (0.42) | HSD11B1HSD11B2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6127508 | 0.85 | HSD11B1 (0.42) | HSD11B1HSD11B2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL27170220 | 0.81 | HSD11B1 (0.32) | HSD11B1HSD11B2 | |
| SCHEMBL30832718 | 0.79 | HSD11B1 (0.44) | HSD11B1HSD11B2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22615698 | 0.78 | HSD11B1 (0.35) | HSD11B1HSD11B2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22581181 | 0.78 | HSD11B1 (0.36) | HSD11B1HSD11B2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124600-A1 | N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124600-A1 | N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists | GRIN2B, GRIN2A, GRIN1 | HSD11B1 1249/4885HSD11B2 1759/4885VNN1 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.